Penumbra, Inc. (PEN) Earnings Call Transcript & Summary
May 4, 2021
Earnings Call Speaker Segments
Stephen Dobson
executiveThanks, operator, and thanks to everyone for being with us today as we go over Penumbra's earnings release for Q1 of 2021. You can find the press release and the financial tables, which include the reconciliation from GAAP to non-GAAP, under the Investors tab on our website, www.penumbrainc.com. On this conference call, the company will be making forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements about our financial performance, commercialization, clinical trials, regulatory status, quality, compliance and business trends. Actual results might differ materially from what those forward-looking statements state or imply because of certain risks and uncertainties, including the ones referenced in our 10-K for the year ended December 31, 2020, filed with the SEC. Therefore, we caution you not to place undue reliance on these forward-looking statements, and we encourage you to review our periodic filings with the SEC, including the 10-K just mentioned, for a fuller discussion of these factors and other risks that could affect our future results or the market price of our stock, including, but not limited to, how the COVID-19 pandemic impacts our business, results of operations and financial condition. Penumbra disclaims any duty to update or revise our forward-looking statements because of new information, future events, developments or otherwise. On this call, certain financial measures are presented on a non-GAAP basis. A reconciliation of GAAP to non-GAAP financial measures appears in our posted press release. We expect the prepared comments on today's call to take roughly 20 minutes. Adam Elsesser, Penumbra's Chairman and CEO, will give a business update; Maggie Yuen, our Chief Financial Officer, will then go over our financial results for the first quarter; and Jason Mills, our Executive Vice President of Strategy, will talk about our updated 2021 guidance. With that, I'd like to hand the call over to Adam Elsesser.
Adam Elsesser
executiveStephen, thank you — and I'm grateful you could fill in for Jee while she's on maternity leave. Hello, everyone, and thanks for joining us for Penumbra's Q1 2021 earnings call. Turning to the quarter: total revenue reached $169.2 million, up 23.2% from a year earlier as reported, or 21.5% on a constant currency basis. Operating income for Q1 2021 was $13.5 million, equal to 8% of revenue, compared with $0.6 million in the prior-year period. Once again, our Vascular segment posted remarkable growth, with revenue climbing 50.5% year over year to $89.2 million — and in our view, we're only at the beginning of what Vascular can do. During Q1, revenue in our Neuro segment came in above what we had projected, reaching $80 million in total — a 2.5% gain compared with the same period a year earlier. After the JET 7 XTRA FLEX recall that occurred in mid-December, the remarkable efforts put in by our Neuro team have set us up favorably for all of 2021 and afterward, as we get ready to bring significant new products to market. On top of that, momentum continues on our REAL Immersive therapeutic platform, and our enthusiasm keeps building around the expanding chances we have to assist patients. Last, we observed healthy momentum internationally, particularly within China. The results from our first quarter show that more patients than at any prior point are benefiting from our products, and yet what motivates us daily is how many patients remain beyond our reach. We've made a point of assembling a genuine lineup of inventive offerings, and that gives us the foundation for lasting expansion. At this point, let me take a moment to walk through how innovation and breadth of portfolio show up in each of these franchises. Beginning with vascular. This quarter, our exclusive Lightning platform, paired with the newest additions to our catheter line, CAT7 and CAT12, delivered robust performance again in peripheral thrombectomy. Physicians are responding to how well, how quickly, and how much benefit these tools provide across both vascular beds, and that's leading more of them to use the products to treat patients who have clots in their bodies. Our Lightning 12 system remains remarkably effective at clearing clots from veins and pulmonary arteries within just one treatment session. Following the FDA's recent clearance of the PE indication, plus the forthcoming rollout of Rapid AI's AI-driven PE platform, we still expect the Lightning franchise to fuel solid expansion for Penumbra in the venous market moving ahead. Regarding the arterial side, we brought Lightning 7 to our customer base late in Q1. The response we've received has been very favorable. Our proprietary hypotube lumen maximizing technology is what CAT7 is built on. For doctors addressing clots in arteries, this delivers a catheter whose outer diameter is reduced while the inner diameter stays largely intact. On top of that, it brings in the major advantages of our own Lightning technology, which supports blood saving and makes the device easier to work with. Thanks to having Lightning 12 alongside Lightning 7, we can now reach a large population of patients with clots in both arteries and veins, spanning the customers we already serve as well as ones we haven't yet won. Bringing this technology to every interventional radiologist, vascular surgeon, and interventional cardiologist won't happen in just 1 or 2 quarters — that's going to take time. Even so, we understand what it means for patients, and our team stays committed to that mission. Turning now to CAT RX, our coronary thrombectomy system: it once again turned in record results. And there's still a very long runway ahead in a market we estimate is roughly the same size as the U.S. stroke market. Late last year, the Society of Cardiovascular Angiography and Interventions updated their guidance so that CAT RX is included as a viable option for treating large thrombus burden in saphenous vein grafts. We're also directing money toward additional clinical studies so that CAT RX can reach more patients in what is a fairly sizable market. In the U.S., our Peripheral Embolization unit turned in yet another quarter at an all-time high, with growth of close to 20% compared with the same period last year. Beyond having a product lineup in this space that no one else offers, we continue to commit resources to innovation there too. As an illustration, Ruby Low Profile, or LP, which is among our most recently launched offerings, delivered another sizable boost to the expansion of Peripheral Embolization during this quarter. Taking a step back on that franchise as a whole, two things stand out to us: fresh doctors are gravitating toward what we offer, and the people already buying from us are using more of it. Put together, peripheral thrombectomy and peripheral embolization keep delivering impressive results, which says a lot about how vital the work our vascular team performs in this area truly is. Let me turn now to Neuro, and I'll start with Neuro Access, where we just recorded our strongest quarter to date. Adoption of BMX96 keeps climbing — roughly twice as many neuro physician customers used it in Q1 as in Q4, the period when we first brought it to market. And it isn't limited to stroke procedures; BMX96 shows up across the full range of neurovascular cases. Access delivered a double-digit increase within the United States by itself, and there's still plenty of runway ahead for that product domestically as well as abroad, since we haven't brought it to international markets yet. The initial traction behind BMX96 shows clearly why innovation and portfolio both matter so much to us. What we offer in Vascular and Neuro isn't just distinctive — those items also link up with one another inside their respective portfolios, so doctors get a full set of solutions aimed at reaching the largest possible number of patients. As we look forward, keeping our attention squarely on innovation and the portfolio, we feel our position is strong for growth down the road across every one of our Neuro franchises: stroke, access embolization — where our SMART COIL line enjoyed its strongest quarter to date — and neurosurgical as well. When it comes to our Neurosurgical business, which tends to get less airtime from us, we posted one of our strongest quarters ever with the Artemis system. Worth pointing out: we're putting money into building the key clinical evidence that we think is needed to eventually make this therapy available to far more ICH patients. Now shifting to our Stroke franchise. Here in the U.S., our business did better than we had expected. The Neuro group delivered remarkable results, showing strength, resilience and expertise in a space we played a key role in establishing more than 10 years ago. A handful of factors strike us as essential in this space. Stroke physicians need access to a comprehensive lineup of innovative products, plus dedication and service toward our customers, and above all, the finest end-to-end solutions for treating stroke in large as well as distal anatomy. Going forward, we are eager to deliver to customers our latest stroke catheters, the RED Series; over the coming months, we aim to roll out RED62, which represents a remarkable leap ahead in stroke intervention for the distal anatomy, enhancing trackability and boosting thrombus removal. In our view, an outsized share of treatable strokes in the distal anatomy remain untreated owing to technological constraints. We see RED62 becoming a flagship product, enabling physicians to treat a greater number of stroke patients in the future. Additionally, we anticipate releasing further catheters in the RED Series shortly after. And we are likewise enthusiastic about our efforts to usher in a fresh paradigm in stroke intervention too. Let me now shift attention to the REAL platform. Our ambitions for REAL keep broadening as we gain more knowledge and spot further chances to assist patients in the areas of physical rehabilitation along with mental and cognitive wellness. We haven't lost sight of how rare this opportunity is—doing something that's never been done before with virtual reality in health care. Our plan is to take our own proprietary tech for fully immersive mobile experiences and bring a genuine immersive therapeutic platform to every place where we think patients could benefit from VR therapy. There's already a substantial amount of clinical evidence showing what virtual reality can do for both rehabilitation and mental health, and our goal is to build on that, working alongside some of the top VR authorities in health care across the globe. A great deal of work lies ahead, and there's a lot still to prove when it comes to REAL in the VR space. Yet daily, we recognize the potential to assist a large number of people. Later this year, once it becomes safe to gather in person, we intend to hold an investor meeting centered on our REAL platform; we will provide updates to everyone in the months ahead. Let's now shift to our international markets. Our business in China, bolstered by the new multifaceted agreement we signed with Genesis MedTech Group in the prior quarter, once again performed strongly in the first quarter; and we are hopeful about further growth opportunities ahead. In Japan, we still anticipate robust growth in 2021 and beyond. We also achieved solid progress across Europe, Latin America and Asia Pacific, despite some pandemic-related impact, and we expect growth in these regions going forward. I will now hand the call to Maggie to review our financial results for the quarter.
Maggie Yuen
executiveThanks, Adam. Good afternoon, everyone. In today's remarks, I'll go over our financial results for the first quarter of 2021. More information will be available in our quarterly reports on Form 10-Q. For the quarter that closed on March 31, 2021, total revenues came to $169.2 million. That represents growth of 23.2% as reported and 21.5% on a constant currency basis versus the first quarter of 2020. In terms of geographic mix, sales during the quarter split 71% U.S. and 29% international. U.S. and international each posted reported growth of 25.4% and 18.2%, respectively, against the same period in 2020. Revenue from our Vascular business reached $89.2 million in the first quarter of 2021, up 50.5% as reported and 49.1% in constant currency versus the same period last year. During the quarter, our Vascular results were fueled by gains in both the thrombectomy and embolization franchises, with growth across Europe and the U.S. Revenue from our Neuro business totaled $80 million in the first quarter of 2021, up 2.5% as reported and 0.6% in constant currency versus the same period a year ago, fueled by gains in our Access franchise across all regions. Our Neuro business rose 0.3% sequentially, fueled by gains in the U.S., Japan and China, partly offset by a decline in Europe and Latin America amid the resurgence of COVID's impact. Gross margin in the first quarter was 65.8%, versus 64.1% in the same quarter last year, and versus Q4 2020 gross margin of 56.5% and non-GAAP gross margin of 65.2%, excluding the product recall impact. We've put additional safety protocols in place at our manufacturing facilities given the resurgence of COVID cases in California early in the year. And I'm proud of how we've kept scaling production capacity to support our expanding portfolio of products. Looking ahead, our gross margin could move slightly because of price and product mix. Total operating expense for the quarter was $97.9 million, or 57.8% of revenue, versus $87.4 million, or 63.6% of revenue, for the same quarter last year. Our research and development expense for Q1 2021 was $18.1 million, versus $12.9 million for Q1 2020. We'll keep investing in product development and platform capabilities. SG&A expenses for Q1 2021 were $79.8 million, versus $74.5 million for Q1 2020. The increase is mainly due to investment in commercial resources, and we've also seen domestic travel and other in-person activities gradually rise over the last few quarters. For the first quarter 2021, we recorded operating income of $13.5 million, or 8% of revenue, versus operating income of $0.6 million for the same period last year. We closed the first quarter with cash, cash equivalents and marketable securities balance of $242.6 million. Cash usage in the quarter is due to the product recall and raw material purchases for new product launches. And now I'd like to turn the call over to Jason to discuss our 2021 guidance.
Jason Mills
executiveThanks, Maggie, and good afternoon, everyone. Along with the release of our first quarter results, we're officially raising the revenue guidance range for 2021 to $695 million to $705 million, which would work out to 24% to 26% growth compared with 2020 revenue of $560.4 million, reflecting the continued momentum we anticipate in our business. This revised guidance is measured against the original 2021 guidance range of $675 million to $685 million that we provided on our fourth quarter call in February. We identify several drivers of growth and still anticipate that our revenue will rise as the year goes on. Looking at it year over year, we expect a greater growth rate in the second quarter, because of the outsized effect of the COVID pandemic in the second quarter of 2020; looking at it quarter over quarter, we expect stronger growth in the back half of the year as we broaden the rollout of new products, among them Lightning 7 and the RED Series of stroke catheters, while hospital value analysis committees work through a number of products introduced during the pandemic. Taken as a whole, and in line with how we have set guidance previously, our revised 2021 revenue guidance reflects present views on our markets, the timing of new product launches and other relevant inputs. I'll now hand the call back to Adam for closing remarks.
Adam Elsesser
executiveThanks, Jason. During the past few quarterly calls, I've recognized the incredible efforts of our customers, how committed our manufacturing staff has been, and the whole group backing that work throughout the worst stretch of the pandemic, plus the remarkable creativity shown by our engineers. Today I want to give particular recognition to our sales and clinical people working in the field across the globe. All of you have remained so dedicated and enthusiastic about showing up for your customers and, by extension, for the patients under their care. Your performance has consistently ranked at the top. Yet over these 12 months, observing how you've engaged and committed yourselves has truly been moving. I should also mention that in the quarter just ended, our sales team suffered the loss of a cherished colleague who passed away far too soon. I'm sure everyone here will join me in honoring his integrity and his remarkable contributions, and in offering our heartfelt sympathies to his spouse and kids. We cherish you, and you will be deeply missed. Thank you. At this point, we'd like to take your questions. Operator, please proceed.
Bob Marcus
analystTo begin with, congrats on an excellent quarter. Adam, I have 2 things I'd like to ask, and I'll put them both out there now. First, it looks like you've built up some strong momentum as you came out of first quarter. It would help to hear how things developed, and especially how you finished the period and what the trends look like so far in second quarter. Then, possibly tied to that, many people worried, once XTRA FLEX was pulled in fourth quarter, that you would shed a sizable portion of those sales. Could you talk about what you've observed in stroke globally, and whether users have moved over and remained on the Penumbra platform?
Adam Elsesser
executiveYes. Thank you, Robbie. Excellent questions; I'll take the first one, about the trends. Without a doubt, certain parts of our business were somewhat slower during the opening weeks of the quarter in January, when the pandemic made things appear, or feel, somewhat harder. Yet, as you're aware, much of our business tends to be more emergent, so perhaps it wasn't affected the way others were; still, without a doubt, we observed improvement as the quarter went on. It's difficult to say, once more, because of how our business works, whether that came mostly from the usual quarterly pattern or from the pandemic. Still, clearly, we feel good about our current position and about the business ahead. Regarding stroke and that business, we've been quite lucky. Without a doubt, there has been considerable trial and movement. We discussed this previously, and on the fourth quarter call, in connection with that business; however, our stroke product line has performed very well, the entire line, the JET 7 standard tip along with the ACE68 in the markets where it's available. And we've watched physicians who tested aspiration catheters from other products and other companies return to us. We believe there's additional opportunity there, and we believe our position is quite strong, both as the RED62 launches and as the other catheters in that series arrive in the back half of the year. So we're feeling optimistic.
Larry Biegelsen
analystAdam, can you hear me?
Adam Elsesser
executiveYes, Larry.
Larry Biegelsen
analystAll right. My phone had an issue, I believe. Sorry about that; I also didn't catch the final portion. I was hoping to ask regarding RED62. Could you speak to the timing? Is this the next-generation workhorse type of aspiration catheter, the sort that will essentially take the place of ACE68, JET 7? And what advantages does this catheter offer compared with the ones we have now? I also had one follow-up.
Adam Elsesser
executiveYes. Thank you, Larry; so we — during the prepared remarks, and I know everybody has a packed day and other companies. So during my prepared remarks, I mentioned that we hope to have that product available within a couple of months, RED62; so RED62 is clearly somewhat smaller than the remaining catheters, and we believe it will be quite significant given the rising interest in conversations about treating a greater number of distal strokes. At present, certain technologies face some constraints in doing that, and we believe RED62 will be fairly important in assisting with treating more and more of those strokes that are — that perhaps aren't being treated today owing to technology constraints. When it comes to the other sizes within the RED Series, we did — I did mention that we will offer additional catheters in the RED Series that will come after RED62 is introduced, though I didn't provide a more specific time frame. But it will come after that time frame I described for 62. So yes, we believe 62 will be significant, but it won't — it isn't intended to take the place of the bigger catheters that will arrive later.
Larry Biegelsen
analystThat's quite useful. Now, a follow-up regarding Lightning 7. Historically, Indigo has been more powerful on the arterial side, I believe, compared to the venous side. Previously, the split was roughly 2/3 to 1/3, with arterial ahead. What's your outlook on how that shifts in 2021 and afterward? Also, could you give us some context around the Lightning 7 launch happening at the close of Q1?
Adam Elsesser
executiveYes. That's actually a great question; and if I had separate sales teams handling the different products — Lightning 7 against Lightning 12 — I would definitely leverage your question to push both to outperform one another; but because it's one single team, I can't pull that off. We view those 2 products as truly complementary. And the amount of work remaining, whether for venous PE or arterial, is so vast. There are so many PE patients we can still assist. So we don't see it as which one will expand quicker, exactly. I believe it will hinge on each one's situation, location, and so forth; but the chance we now have, having extended Lightning technology to both sides and genuinely upgraded the catheter tech with things like CAT7, CAT12 featuring the new — pardon me, hypotube technology that's proving really, really effective. I believe we'll achieve genuine success across both those areas. Which one will surpass the other? It's tough to say at this point; and hopefully they're both — they both do well. I think patients will gain.
Brandon Vazquez
analystThis is Brandon, filling in for Margaret. To start, I have a question about guidance. If I assume fairly modest quarter-over-quarter gains in the Vascular segment, perhaps that's arguably somewhat cautious, considering the momentum from upcoming product launches. It sort of — it appears to suggest that a low double-digit growth rate is baked into guidance for the Neuro portfolio. Is that math correct? And is that roughly how you all are thinking internally about the split between peripheral and Neuro growth across the year?
Jason Mills
executiveBrandon, great to hear from you; this is Jason. I'll handle that one, and then perhaps Adam can chime in, if he'd like to. Obviously, we don't break out growth expectations between Vascular and Neuro. So the commentary was intended to help on a — both a year-over-year and a quarter-over-quarter basis. It seems like you heard and grasped that guidance from an overall perspective quite well; we also noted that in the back half of the year, we anticipated sequential growth would be bigger. And we called out products on both the Vascular and the Neuro side. So I think those remarks about the overall business, clearly, since we were highlighting products in both franchises, apply, respectively.
Brandon Vazquez
analystAll right, that's useful. Now turning to the Vascular segment — that business keeps delivering outstanding results. I wanted to ask whether you could describe, out in the field, what looks different versus 12 months ago? Twelve months back, that business was expanding strongly both sequentially and year over year. And it appears that over the past maybe 2 quarters, it has really swung to the positive side and improved further. What has shifted out in the field across the last couple of quarters? And I suppose part of what I'm asking is to grasp what has shifted and how sustainable that shift is?
Adam Elsesser
executiveYes. Brandon, thank you. That's an excellent question. A few things have shifted, and perhaps it's really a mix of all of it. The first and most evident, naturally, is the release of our new catheters in Lightning. Those together, truly, with the engineering inside those catheters that lets them behave as they do — tracking well while offering, you know, the bigger lumen alongside the smaller outer diameter — has proven enormously valuable. And then you put that alongside Lightning, which delivers both blood saving and, most importantly, ease of use for the customers, and the response has simply been remarkable. So the product has genuinely advanced. As you're aware, we take on these domains, such as blood clot within the body, and we simply continue innovating and innovating until those cases get simpler and simpler. And this represents a major leap forward in that technology. You put that together with the emphasis on the need for single session treatment, where the patient wouldn't need to spend time in an ICU or a monitored bed, as happens when they receive lysis, and the demand for that throughout the pandemic last year, I believe, brought — greater attention to the need to remove blood clot in single sessions. So I believe it's a mix of those factors. I also — there are other companies pursuing the same objective with different technology, and that is generating more and more awareness. When you total it all up, I think people are now centered on the notion that there are plenty of folks, who have blood clots in their body and what we were doing is not as good as what we can do. And so we hold a great deal of optimism. Regarding how durable, I believe it's very durable. And as you know from our history, even though Lightning and CAT7 and 12 represent really an enormous step up, we aren't finished innovating. And so we intend to keep advancing this and advancing this until removing blood clot turns into a relatively straightforward and not a significant procedure. And we believe reaching that point is possible; so indeed, my view is that this will hold up for a good while.
Bob Hopkins
analystI'd like to ask about 2 more items, if that's all right. First, regarding China — you all included disclosures showing a fairly strong revenue figure from China during Q4. What I'd like to know is how things unfolded once Q1 came around. Was the revenue roughly at the same level? And beyond that, perhaps you could share your broader view on what China looks like for the rest of this year.
Adam Elsesser
executiveSure. Appreciate that, Bob. That's a really good thing to ask about. When we reported that quarter, we let everyone know about the arrangement we entered into with Genesis — it's truly a multi-part agreement involving approximately 5 of the products in our Neuro line; and our belief is that it holds significant promise for us across the coming years. That said, as I mentioned during today's prepared remarks, this is only the start; we believe there's additional opportunity beyond even that within China. So to answer you, China delivered yet another solid quarter for us; and looking ahead, our expectation is that it will keep serving a key role for the company. We're enthusiastic about the chance to introduce this technology initially via those Neuro products and subsequently extend it throughout our broader portfolio into that nation.
Bob Hopkins
analystSo there are 2 other items on that. First, if we look back at the 2019 Analyst Day, you all pointed to quite a few fresh opportunities. I understand China was one you saw playing out across a great many years, but you still called it out as an opportunity worth multiple billions of dollars. That's the piece I'm attempting to probe a bit and figure out when it might turn into a bigger portion of the narrative? So I suppose, to dig a little deeper into whatever you're comfortable revealing, do you believe you'll keep seeing gains relative to that Q4 baseline? Did you observe that during Q1? Would you anticipate it across the remainder of the year? Then the second item I'd really like your perspective on. Regarding stroke, you mentioned a few things for this year, including some fresh product introductions and also a paradigm shift. My assumption is we haven't yet heard about that paradigm shift.
Adam Elsesser
executiveYes. Great questions indeed. We won't begin citing particular figures for our markets; however, the business for us in China, obviously, we believe, is fairly sizable; and once more, on a quarter-by-quarter basis, we won't cite those particular figures; however, it delivered again this quarter. We noted that during the prepared remarks, and it was a meaningful benefit, though not a dominant one. The remaining business delivered too; so please don't view it as one or the other. When it comes to stroke, we — the moment we're able, the moment it's suitable given the competitive landscape, I am eager to reveal the products that — the product I've hinted at as being part of a paradigm shift; however, for clear competitive reasons, which I believe everybody would grasp, as you're aware, we now have roughly 15 companies competing in stroke; we'll hold off on revealing that until the very last moment, yet it's on its way. And my confidence about it is as strong as it has ever been. And I believe it will be truly, truly significant for patients.
Stephen Dobson
executiveThanks, operator. Our management team and I want to express our appreciation once more for everyone being here with us today, and for the attention you've shown toward Penumbra. We're eager to share our latest news with all of you on the call for the second quarter.
Operator
operatorThis concludes today's conference call. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Penumbra, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Penumbra, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Penumbra, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.